TY - JOUR
T1 - Neuroprotective effect of 5-HT3 receptor antagonist on ischemia-induced decrease in CA1 field potential in rat hippocampal slices
AU - Kagami-ishi, Yoshifumi
AU - Shibata, Shigenobu
AU - Watanabe, Shigenori
PY - 1992/11/24
Y1 - 1992/11/24
N2 - The effect of 5-HT3 receptor agonists and antagonists on the hypoxia/hypoglycemia (ischemia)-induced decrease in CA1 field potential elicited by stimulation of Schaffer collaterals was investigated using rat hippocampal slices. Treatment with the 5-HT3 receptor agonist, 2-methyl-5-HT (1-10 μM), exaceebated the ischemia-induced decreased in CA1 field potential, whereas treatment with the 5-HT3 receptor antagonist. Y-25130 (0.1-100 μM), or the 5-HT2 receptor antagonist, ketanserin (10, 100 μM), produced dose-dependent neuroprotection against the ischemia-induced decrease. However, in normal non-ischemic solution these treatments did not significantly change the CA1 field potential. The protective action of Y-25130 was blocked by co-treatment with 2-methyl-5-HT. The magnitude of protection in the Y-25130-treated group (EC50, 1.8 μM) was about 20 times greater than that in the ketanserin-treated group (EC50, 33 μM). The present study demonstrated that stimulation of 5-HT3 receptors plays a detrimental role in the development of ischemic damage, whereas blockade of the 5-HT3 receptor plays a neuroprotective role in ischemic damage, suggesting a facilitatory role of 5-HT neurons in ischemia-induced neuronal deficits.
AB - The effect of 5-HT3 receptor agonists and antagonists on the hypoxia/hypoglycemia (ischemia)-induced decrease in CA1 field potential elicited by stimulation of Schaffer collaterals was investigated using rat hippocampal slices. Treatment with the 5-HT3 receptor agonist, 2-methyl-5-HT (1-10 μM), exaceebated the ischemia-induced decreased in CA1 field potential, whereas treatment with the 5-HT3 receptor antagonist. Y-25130 (0.1-100 μM), or the 5-HT2 receptor antagonist, ketanserin (10, 100 μM), produced dose-dependent neuroprotection against the ischemia-induced decrease. However, in normal non-ischemic solution these treatments did not significantly change the CA1 field potential. The protective action of Y-25130 was blocked by co-treatment with 2-methyl-5-HT. The magnitude of protection in the Y-25130-treated group (EC50, 1.8 μM) was about 20 times greater than that in the ketanserin-treated group (EC50, 33 μM). The present study demonstrated that stimulation of 5-HT3 receptors plays a detrimental role in the development of ischemic damage, whereas blockade of the 5-HT3 receptor plays a neuroprotective role in ischemic damage, suggesting a facilitatory role of 5-HT neurons in ischemia-induced neuronal deficits.
KW - (In vitro)
KW - 5-HT (5-hydroxytryptamine, serotonin)
KW - 5-HT receptors
KW - CA1 field potential
KW - Hippocampus
KW - Hypoxia/hypoglycemia
KW - Ischemia
UR - http://www.scopus.com/inward/record.url?scp=0026574860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026574860&partnerID=8YFLogxK
U2 - 10.1016/0014-2999(92)94817-F
DO - 10.1016/0014-2999(92)94817-F
M3 - Article
C2 - 1451743
AN - SCOPUS:0026574860
SN - 0014-2999
VL - 224
SP - 51
EP - 56
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1
ER -